New hope for ALS patients: experimental drug CNM-Au8 now available through expanded access

NCT ID NCT06408727

TEMPORARILY_NOT_AVAILABLE Disease control Sponsor: Clene Nanomedicine Source: ClinicalTrials.gov ↗

First seen Apr 10, 2026 · Last updated May 09, 2026 · Updated 7 times

Summary

This program provides early access to an experimental drug called CNM-Au8 for people with amyotrophic lateral sclerosis (ALS), a progressive nerve disease. Participants must be 18 or older with a confirmed ALS diagnosis and able to take the medication by mouth. The goal is to offer treatment before the drug is fully approved, while gathering safety information.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Columbia Unniversity

    New York, New York, 10032, United States

  • Duke University

    Durham, North Carolina, 27704, United States

  • Northwestern University

    Chicago, Illinois, 60611, United States

  • Nova Southeastern University

    Fort Lauderdale, Florida, 33328, United States

  • Pennsylvania State University

    Hershey, Pennsylvania, 17033, United States

  • Synapticure

    Chicago, Illinois, 60613, United States

  • Texas Neurology

    Dallas, Texas, 75206, United States

  • University of Iowa

    Iowa City, Iowa, 52242, United States

Conditions

Explore the condition pages connected to this study.